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We thank Mattias Bronström for his interest in our Article.1 The Da Qing Diabetes 
Prevention Study was not terminated prematurely, but ran the planned full course of 6 years 
of intervention.2 Subsequently, 20 years after the initial randomisation, we designed and 
implemented an observational follow-up study with prespecified outcomes and reported the 
results on the macrocomplications and microcomplications of diabetes.3,4 Because of 
potentially very important, but non-significant, trends in mortality seen in the 20 year 
followup, a subsequent follow-up at 23 years was specifically designed to determine 
whether the death rates between the lifestyle intervention and control groups continued to 
diverge.1
The observation of a greater effect of lifestyle intervention in women, which was the result 
of a post-hoc analysis, was not anticipated and the explanations remain unclear. Given its 
level of statistical significance, we believe that this result needed to be reported. However, 
we do share some of Bronström’s hesitation to accept its magnitude at face value. More 
importantly, as the first report of a randomised controlled trial to show statistically 
significant reduction in mortality rates after lifestyle intervention in patients with impaired 
glucose tolerance,1 replication of the findings from continuing studies such as The Diabetes 
Prevention Program Outcomes Study (DPPOS)5 will be important to determine the extent to 
which our results can be generalised.
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